TB-500

TB-500 is a short synthetic peptide corresponding to a fragment of thymosin β4, a 43-residue actin-sequestering protein found in most mammalian cell types. The fragment contains the region carrying the conserved actin-binding motif that gives the parent protein its function, which is why it is used as a minimal structural proxy for thymosin β4 in binding and migration assays. It is important not to conflate the two: TB-500 is the fragment, not the full-length protein, and the literature reports differing behaviour between them in several experimental systems.

Thymosin β4 itself was identified in thymic extracts in the mid-1960s and later reclassified once its principal biochemical role — sequestering monomeric G-actin and thereby buffering the pool available for filament assembly — was characterised. Interest in a short synthetic fragment followed from that work: if the actin-binding activity localises to a defined motif, a synthesisable fragment becomes a far more tractable reagent than a recombinant 43-residue protein. TB-500 is the product of that logic, and much of the comparative literature is explicitly about how far the fragment reproduces the parent.

Research contexts centre on cytoskeletal dynamics. The peptide appears in in-vitro studies of G-actin sequestration and actin polymerisation kinetics, in endothelial and epithelial cell-migration and wound-closure assays, and in angiogenesis models where endothelial tube formation is the readout. Work in animal models of cardiac and corneal injury also appears in the literature, alongside investigation of downstream pathways including integrin-linked kinase and Akt signalling. Reported observations in all of these belong to the primary studies concerned and are not presented here as demonstrated effects or uses.

For a fragment peptide, analytical characterisation answers a question that goes beyond simple purity: whether the material actually is the intended fragment. Sequence-adjacent fragments of a common parent protein are difficult to distinguish by eye and easy to substitute, so mass-spectrometric identity confirmation of the exact molecular mass is the decisive datum, with HPLC establishing purity and resolving deletion sequences from synthesis. Because the whole rationale for using the fragment rests on it carrying the correct binding motif intact, batch-level identity data is what makes an actin-binding result interpretable at all.

Within this catalogue, TB-500 contrasts most directly with BPC-157. Both recur in tissue-model research and are often discussed together, but structurally they share nothing: TB-500 derives from a characterised endogenous protein with a known biochemical mechanism, while BPC-157 is a synthetic sequence whose mechanism remains a subject of investigation. Comparisons between fragment and full-length thymosin β4 are a more meaningful axis of study than comparisons across unrelated peptide classes.